- Home
- NVAX vs PEB Comparison
NVAX vs PEB Comparison
Compare NVAX & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- PEB
- Stock Information
- Founded
- NVAX 1987
- PEB 2009
- Country
- NVAX United States
- PEB United States
- Employees
- NVAX N/A
- PEB N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- PEB Real Estate Investment Trusts
- Sector
- NVAX Health Care
- PEB Real Estate
- Exchange
- NVAX Nasdaq
- PEB Nasdaq
- Market Cap
- NVAX 2.0B
- PEB 1.7B
- IPO Year
- NVAX 1995
- PEB 2009
- Fundamental
- Price
- NVAX $11.63
- PEB $12.41
- Analyst Decision
- NVAX Buy
- PEB Hold
- Analyst Count
- NVAX 5
- PEB 7
- Target Price
- NVAX $15.80
- PEB $14.42
- AVG Volume (30 Days)
- NVAX 5.1M
- PEB 1.8M
- Earning Date
- NVAX 08-08-2024
- PEB 07-24-2024
- Dividend Yield
- NVAX N/A
- PEB 0.32%
- EPS Growth
- NVAX N/A
- PEB N/A
- EPS
- NVAX N/A
- PEB N/A
- Revenue
- NVAX $987,667,000.00
- PEB $1,441,066,000.00
- Revenue This Year
- NVAX N/A
- PEB N/A
- Revenue Next Year
- NVAX N/A
- PEB $3.13
- P/E Ratio
- NVAX N/A
- PEB N/A
- Revenue Growth
- NVAX N/A
- PEB 1.03
- 52 Week Low
- NVAX $3.53
- PEB $11.39
- 52 Week High
- NVAX $23.86
- PEB $16.65
- Technical
- Relative Strength Index (RSI)
- NVAX 44.54
- PEB 41.37
- Support Level
- NVAX $11.26
- PEB $12.71
- Resistance Level
- NVAX $13.84
- PEB $13.39
- Average True Range (ATR)
- NVAX 0.89
- PEB 0.36
- MACD
- NVAX 0.04
- PEB -0.00
- Stochastic Oscillator
- NVAX 22.15
- PEB 2.83
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper-upscale and luxury hotels with 11,924 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in December 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.